| 33.70 Delayed Data As of 4:00pm ET |  +0.30 / +0.90%Today’s Change | 29.22 Today|||52-Week Range 69.76 | +2.53% Year-to-Date |
| First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory C... Jun 13 / PR NewswirePRN - Paid Partner Content | Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound? Jun 07 / Zacks.comZAK - Paid Partner Content |
| Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analys... Jun 11 / PR NewswirePRN - Paid Partner Content | Cancer-Fighting Stocks & ETF: What You Need to Know Jun 05 / Zacks.comZAK - Paid Partner Content |
| Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Jun 11 / Zacks.comZAK - Paid Partner Content | Nektar (NKTR) in Focus: Stock Moves 8.8% Higher Jun 04 / Zacks.comZAK - Paid Partner Content |
| Previous close | 33.40 |
| Today’s open | 33.80 |
| Day’s range | 33.30 - 34.24 |
| Volume | 906,995 |
| Average volume (3 months) | 1,673,080 |
| Market cap | $5.8B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -181.05% |
| Earnings growth (next 5 years) | -7.38% |
| Revenue growth (last year) | +287.81% |
| P/E ratio | 9.1 |
| Price/Sales | 4.96 |
| Price/Book | 3.37 |
| Today’s change | Today’s % change | |
|---|---|---|
| BLUEbluebird bio Inc | +5.04 | +4.28% |
| MRNAModerna Inc | +0.37 | +2.40% |
| BPMCBlueprint Medicines ... | +3.74 | +4.12% |
| NBIXNeurocrine Bioscienc... | +2.10 | +2.50% |
| Next reporting date | August 5, 2019 |
| EPS forecast (this quarter) | -$0.80 |
| Annual revenue (last year) | $1.2B |
| Annual profit (last year) | $681.3M |
| Net profit margin | 57.09% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Howard W. Robin |
Chief Operating Officer & Senior Vice President John Nicholson |
Corporate headquarters San Francisco, California |
